Elevated level of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancer

Table 1 Cyclin B1 expression status of 34 gastric cancer tissues with or without MAD2 overexpression

	Cyclin B1 level
	T > N	T = N
MAD2 level
T > N (n = 25)	16	9
T = N (n = 9)	2	7
	P = 0.038

T: tumorous tissue; N: non-tumorous tissue.

Table 2 Cell cycle phase fractions of 29 gastric cancer tissues with or without MAD2 overexpression (mean ± SD)

	Phase fraction (%)
	G0/G1	S	G2/M
MAD2 level
T > N (n = 20)	80.8 ± 5.9	8.6 ± 7.0	10.6 ± 4.9
T = N (n = 9)	83.5 ± 7.4	9.9 ± 7.7	6.4 ± 4.0
	P = 0.301	P = 0.657	P = 0.033

T: tumorous tissue; N: non-tumorous tissue.

Table 3 DNA ploidy status of 32 gastric cancer tissues with or without MAD2 overexpression

	Diploidy	Aneuploidy
MAD2 level
T > N (n = 23)	10	13
T = N (n = 9)	4	5
	P = 1.000

T: tumorous tissue; N: non-tumorous tissue.

Table 4 Relationships between elevated MAD2 levels and clinicopathological characteristics (mean ± SD)

	MAD2 level
	T > N (n = 25)	T = N (n = 9)	P
Age (yr)	62.8 ± 10.3	66.4 ± 5.0	0.325
Sex (male/female)	19/6	6/3	0.586
Site of tumor			0.828
Upper stomach	4	2
Middle stomach	6	2
Lower stomach	14	4
Whole stomach	1	1
Size of tumor (cm)	7.3 ± 2.3	8.0 ± 2.9	0.470
Grade of cell differentiation			0.146
Well differentiated	1	0
Moderately differentiated	13	8
Poorly differentiated	11	1
Borrmann type			0.664
0	2	0
1 + 2	6	2
3 + 4	17	7
Stromal reaction			0.739
Medullary type	6	3
Intermediate type	12	3
Schirrhous type	7	3
Infiltration type			0.475
α	4	2
β	8	1
γ	13	6
Lauren histological classification			0.448
Intestinal type	13	3
Diffuse type	12	6
Lymph node metastasis (Yes/No)	15/10	6/3	1.000
Lymphatic duct invasion (Yes/No)	18/7	7/2	1.000
Vascular invasion (Yes/No)	2/23	1/8	1.000
Liver metastasis (Yes/No)	1/24	0/9	1.000
Peritoneal dissemination (Yes/No)	2/23	1/8	1.000
Depth of cancer invasion			0.738
Mucosa, submucosa	1	0
Propria muscle, subserosa	5	1
Serosa	18	8
Serosa (infiltration) exposed	1	0
TNM stage			0.932
I	3	1
II	8	2
III	8	3
IV	6	3
Five-yr overall survival rate	48.0%	20.8%	0.478
Five-yr disease-free survival rate	46.3%	11.1%	0.229